Surabhi Upadhyay

Articles By

Surabhi Upadhyay

Associate Editor - Personal Finance and Senior Anchor

Articles By Surabhi Upadhyay

Reliance New Energy Solar to acquire Faradion Limited; expert evaluates deal

Reliance New Energy Solar to acquire Faradion Limited; expert evaluates deal
energy | IST

Are hospitals geared up for rising Omicron cases? Experts discuss

Are hospitals geared up for rising Omicron cases? Experts discuss
healthcare | IST

Worst over for Bank Nifty; positive on pharma, IT indices: Goldilocks Premium Research

Worst over for Bank Nifty; positive on pharma, IT indices: Goldilocks Premium Research
market | IST

V-Mart Retail doesn’t expect a big drop in revenue due to rise in COVID cases

V-Mart Retail doesn’t expect a big drop in revenue due to rise in COVID cases
retail | IST

Oil prices rise 60% in 2021, what's the outlook for 2022? Experts decode

Oil prices rise 60% in 2021, what's the outlook for 2022? Experts decode
market | IST

Buy Nureca, Anupam Rasayan, add Latent View, Supriya Life on dips: IIFL’s Sanjiv Bhasin

Buy Nureca, Anupam Rasayan, add Latent View, Supriya Life on dips: IIFL’s Sanjiv Bhasin
market | IST

Indian funds had good 2021; China to see substantial flows in 2022: EPFR Global

Indian funds had good 2021; China to see substantial flows in 2022: EPFR Global
market | IST

Expect technology-linked job market to remain strong: TeamLease

Expect technology-linked job market to remain strong: TeamLease
business | IST

Prestige Estate likely to exceed FY21 sales; says strong demand to continue in 2022

Prestige Estate likely to exceed FY21 sales; says strong demand to continue in 2022
real estate | IST

Have adequate semiconductors to address demand: Kalyani Steels

Have adequate semiconductors to address demand: Kalyani Steels
business | IST

RBI's financial stability report: Bad loans may rise to 9.5%, experts weigh in

RBI's financial stability report: Bad loans may rise to 9.5%, experts weigh in
economy | IST

Explained: Who should get monoclonal antibody therapy?

Explained: Who should get monoclonal antibody therapy?
healthcare | IST

Nirmal Bang prefers HCL Tech, Tech Mahindra; advises to buy Nykaa on dips

Nirmal Bang prefers HCL Tech, Tech Mahindra; advises to buy Nykaa on dips
market | IST

Blue Dart bets on growth story as Omicron impact unlikely to be severe

Blue Dart bets on growth story as Omicron impact unlikely to be severe
business | IST

Like home improvement, realty, specialty chemical spaces: Kotak MF's Harsha Upadhyaya

Like home improvement, realty, specialty chemical spaces: Kotak MF's Harsha Upadhyaya
market | IST